Baxter Hlthcare

AUG 31, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Cefazolin (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval of labeling changes for cefazolin formulations; no clinical trial data or efficacy evidence is reported in this regulatory record.

AUG 6, 2026 · REGULATORY APPROVAL

FDA approval: Levetiracetam

U.S. Food and Drug Administration

FDA approval of an intravenous levetiracetam formulation; establishes regulatory authorization but does not report clinical trial data or efficacy outcomes.

JUN 11, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Dextrose (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for dextrose labeling; describes a regulatory action, not clinical evidence of efficacy or safety.

APR 15, 2026 · REGULATORY APPROVAL

FDA approval: Dexmedetomidine Hydrochloride

U.S. Food and Drug Administration

FDA approval of dexmedetomidine hydrochloride generic injectable formulation; regulatory action establishing product availability but does not report clinical trial efficacy or safety data.

MAR 30, 2026 · REGULATORY APPROVAL

FDA approval: Epinephrine (New Combination and New Formulation or New Manufacturer)

U.S. Food and Drug Administration

FDA approval of a new formulation and manufacturer of epinephrine; this is a regulatory action, not a clinical efficacy study, and does not establish comparative clinical benefit.